Merck & Co., Inc. (NYSE:MRK) reached 31.07% versus a 1-year low price of $63.53. The stock was last seen 0.95% higher, reaching at $83.27 on 7/30/2019. At a recent session, the prices were hovering between $82.82 and $85.173. This company shares are 10.65% off its target price of $92.14 and the current market capitalization stands at $215.23B. The recent change has given its price a 1.02% lead over SMA 50 and -4.36% deficit over its 52-week high. The stock witnessed -0.69% declines, 5.79% gains and 13.71% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MRK’s volatility during a week at 1.83% and during a month it has been found around 1.78%.
What Does Merck & Co., Inc. (MRK) Do?
The company describes itself in regulatory filings as, “Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company’s relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.” [Text can be found here: https://www.marketwatch.com/investing/stock/MRK/profile under company description.]Merck & Co., Inc. (MRK) Top Holders
Institutional investors currently hold around $162.09 billion or 78.2% in MRK stock. Look at its top three institutional owners: Vanguard Group Inc owns $17.14 billion in Merck & Co., Inc., which represents roughly 7.96% of the company’s market cap and approximately 10.58% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 187,465,828 shares of the stock are valued at $15.46 billion. The third largest holder is State Street Corp, which currently holds $9.67 billion worth of this stock and that ownership represents nearly 4.49% of its market capitalization.
At the end of March reporting period, 991 institutional holders increased their position in Merck & Co., Inc. (NYSE:MRK) by some 82,699,268 shares, 1,091 decreased positions by 100,117,434 and 284 held positions by 1,782,000,000. That puts total institutional holdings at 1,965,000,000 shares, according to SEC filings. The stock grabbed 121 new institutional investments totaling 9,596,151 shares while 92 institutional investors sold out their entire positions totaling 10,580,119 shares.Merck & Co., Inc. (NYSE:MRK) Insider Trades
Multiple company employees have indulged in significant insider trading. Merck & Co., Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP, Global Svcs & CFO Davis Robert M has sold 216,718 shares of Merck & Co., Inc. (MRK) in the trading session dated Jun. 25, 2019. These shares are worth $18,514,219 and were traded at $85.43 each. The SEC filing shows that Clyburn Frank performed a sale of 25,000 shares. The EVP, Chief Commercial Officer disposed these shares by way of transaction on May. 07, 2019. The company’s shares were given away at $77.73 per share worth to an income of some $1,943,250 to the account of Clyburn Frank.
EVP&Pres, Merck Animal Heallth, DeLuca Richard R., sold 35,000 common shares of Merck & Co., Inc. (MRK) in the open market. In a transaction dated May. 03, 2019, the shares were put up for sale at an average price of $80, raking in a sum of $2,800,000. After this sale, 72,138 common shares of MRK are directly owned by the insider, with total stake valued at $6,006,939.
In the transaction dated Mar. 25, 2019, a great number of shares sold came courtesy the EVP, Global Svcs & CFO; Davis Robert M disposed a total of 192,572 shares at an average price of $82.38, amounting to approximately $15,864,081. The insider now directly owns 137,660 shares worth $11,462,928.Merck & Co., Inc. (MRK) Analyst Guide
Several analysts have released their opinion on Merck & Co., Inc. (NYSE:MRK), with 8 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.62 average brokerage recommendation [T1].